eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.
In cancer, the tightly controlled translation of certain messenger RNA, or mRNA, frequently becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastasis. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.